Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that for postmenopausal patients with advanced breast cancer, quality of life, overall survival, and progression-free survival are the most important factors in treatment decisions, while side effects hold less importance.

In this pilot study, the CNC® device improved body image perceptions in patients with chemotherapy-induced alopecia but did not significantly affect psychological wellbeing; it may help prevent discomfort and enhance everyday life compared to traditional wigs.

This study found that a nutritional teaching program significantly reduced chemotherapy side effects and improved the health status of breast cancer patients undergoing chemotherapy.

This article highlights exosome-based targeted drug delivery using DARPin G3 proteins as a promising approach for treating aggressive HER2-positive breast cancer but reports no new clinical results.

This study explored the effects of various nutraceutical ingredients on breast cancer cell lines but found no conclusive information regarding their interaction with tamoxifen therapy.

In this study, patients with breast cancer who received alternative and complementary therapy with culinary mushrooms exhibited improved health outcomes and reduced costs compared to conventional treatments.

This study developed a novel FRET-based 3D in vitro breast tumor model that can non-invasively evaluate drug-induced effects, showing its potential as an intermediary screening platform for cancer drugs.

Using a niacinamide cream can improve life quality for breast cancer patients during chemotherapy.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

In this study, among patients undergoing chemotherapy for breast or gynecologic cancers, smell and taste functions significantly decreased but largely recovered three months post-treatment, with taxane-based regimens causing more severe taste disturbances.

This study found that baicalin delivery through polymeric nanocapsules significantly enhanced its anticancer activity in breast cancer cell lines MCF-7 and MDA-MB-231.

This study found that glibenclamide exhibited a cytostatic effect on MDA-MB-231 breast cancer cells, potentially mediated through K ATP channels, and enhanced the antiproliferative impact of doxorubicin.

In this study, hair samples from breast cancer patients showed increased β-sheet structures and lipid content, with spectral markers successfully identifying cancer in a blind test but also producing false positives.

This study found that the combination of letrozole and quercetin loaded in spanlastics showed enhanced cytotoxicity and other anticancer effects against MCF-7 breast cancer cells compared to individual treatments.

In this study, scalp hypothermia with the Theracool™ cooling machine was largely ineffective for preventing alopecia in breast cancer patients undergoing a chemotherapeutic regimen including cyclophosphamide and anthracyclines.

This study found that the safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in Germany align with existing clinical trial data.

In this study, there was no evidence that using 5α-reductase inhibitors for either short or long durations increased the risk of male breast cancer.

In this study, both honey and bee pollen may alleviate menopausal symptoms in breast cancer patients on antihormonal treatment, with no significant difference between the two.

This study found that dihydrotestosterone (DHT) regulates the degradation of p27 in MCF-7 breast cancer and OVCAR-3 ovarian cancer cells, involving SKP2 as a key factor.

This study identified common symptoms and side effects experienced by women with hormone receptor-positive, HER2-negative advanced breast cancer, including fatigue, hair loss, and impacts on daily activities and mobility.

This study highlights the significant impact of eyebrow and eyelash loss during chemotherapy on women's quality of life, noting both emotional and physical challenges.

This study found that sacituzumab govitecan improved health-related quality of life in most areas for patients with HR+/HER2− metastatic breast cancer compared to chemotherapy, except for increased diarrhea, supporting its use as a treatment option.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

This study concluded that both vaginal TEST and Estring may be effective for treating vaginal dryness in breast cancer patients on aromatase inhibitors, with adverse events being rare and manageable.

This study reports that health-related quality of life was generally maintained, and sometimes improved, in patients with HR+/HER2- advanced or metastatic breast cancer treated with palbociclib, compared to monotherapy, across various study types.

This study found that compounds isolated from the Etlingera alba rhizome exhibited cytotoxic and anti-metastatic activity, with potential for development against Triple-Negative Breast Cancer.

This review highlights the significant impact of cutaneous and oral mucosal adverse events on patients undergoing breast cancer treatment, emphasizing the need for early detection and comprehensive management to maintain treatment adherence and enhance patient care.

In this descriptive study, researchers assessed the most common short-term side effects of anthracycline and taxane-based chemotherapy in 122 Moroccan women with localized breast cancer, documenting frequent systemic, gastrointestinal, dermatological, neurological, musculoskeletal, and ocular toxicities.

This article describes how PESCADOR software assists in creating detailed biological pathway charts from PubMed abstracts, focusing on hair and breast development case studies without providing new clinical results.

This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.